CompanySCYXNasdaqJersey City, NJ

Scynexis Inc

Scynexis develops antifungal compounds and SCY-770, a treatment for autosomal dominant polycystic kidney disease with orphan drug designation.

SEC EDGAR ClinicalTrials.gov scynexis.com

8-KSep 28Latest SEC filing

Sep 28Latest story

September 2026

Scynexis gets BARDA award worth up to $214 million for antifungal SCY-247

Sep 28PartnershipScynexis Inc

SCYNEXIS names Steven K. Burke to board as ADPKD program advances

Sep 22PeopleScynexis Inc

Scynexis names Sanjay Subramanian as CFO, replacing retiring Ivor Macleod

Sep 10PeopleScynexis Inc

August 2026

Scynexis posts results for terminated Phase 3 MARIO trial in invasive candidiasis

Aug 10Trial updateechinocandin Scynexis Inc